Menveo, manufactured by Novartis, received approval for use in 2010 to vaccinate against Neisseria meningitidis serogroups A, C, Y and W-135. It is approved for use in people 11 to 55 years of age. Menveo Vaccine Package Insert Approval History, Letters, Reviews, and Related Documents – Menveo March 27, 2017